Aldeyra Therapeutics, Inc. [ALDX] Securities Class Action Lawsuit Update

• Case Name: Kirby v. Aldeyra Therapeutics, Inc.
• Case No.: 1:26-cv-11510
• Jurisdiction: United States District Court, District of Massachusetts
• Filed on: March 30, 2026
• Class Period: November 3, 2023 – March 16, 2026, inclusive

Introduction

Aldeyra Therapeutics, Inc. faces a securities class action after investors alleged the company repeatedly told the market that its dry eye drug candidate, reproxalap, had shown “broad-based, rapid-onset activity and consistent safety” across multiple Phase 2 and Phase 3 studies, even as the underlying trial results were allegedly inconsistent and unreliable.

The lawsuit centers on a simple causal chain: repeated confidence in clinical efficacy, a sudden FDA Complete Response Letter, and a one-day collapse in shareholder value. On March 17, 2026, the alleged truth began to emerge through the FDA’s Complete Response Letter. The FDA said the application lacked substantial evidence of efficacy and that inconsistent study results raised “serious concerns about the reliability and meaningfulness of the positive findings.”

ALDX stock fell 70.7% that day. For investors, the case now turns on whether those earlier assurances were unsupported when made.

“Most ALDX shareholders never file or join the class action, which means they miss out on potential recovery funds,” said Attorney Joseph Levi.

Backdrop and Business Context

Aldeyra describes itself as a biotechnology company focused on immune-mediated diseases, with reproxalap positioned as a first-in-class reactive aldehyde species inhibitor for dry eye disease. For years, reproxalap served as both product thesis and platform proof point. The company’s public filings repeatedly used the candidate as validation for its broader RASP science engine.

That framing matters. Investors were not simply buying a single asset outcome; they were buying the credibility of an entire scientific platform. The complaint alleges that this credibility was built through recurring SEC disclosures in 10-Q and successive 10-K filings from 2023 through 2025, each reinforcing the same core narrative of efficacy, consistency, and clinical relevance.

In development-stage biotech, a lead asset can heavily influence valuation and strategy. Here, the complaint portrays reproxalap as central to Aldeyra’s public narrative.

Promises Made vs. Reality

The complaint quotes Aldeyra’s SEC filings as stating that reproxalap had demonstrated “consistent statistically significant and clinically relevant activity” in dry eye disease studies, with symptom relief occurring within minutes of dosing. Those statements were repeated across the FY23, FY24, and FY25 annual reports, signed by senior leadership including CEO Todd Brady and finance officers Michael Alferi and Bruce Greenberg.

Investors allege the reality was different: the trial results were inconsistent, any positive findings were therefore unreliable and not meaningful, and defendants knew or recklessly disregarded that their efficacy statements lacked a reasonable basis. The sharpest contrast arrived in the FDA’s own words, quoted in the complaint: “the inconsistency of study results raises serious concerns about the reliability and meaningfulness of the positive findings.” That language closely tracks the lawsuit’s central theory and is likely to feature prominently in the case.

Timeline of Alleged Misconduct and Disclosures

The alleged timeline is unusually clean.

The class period begins on November 3, 2023, when Aldeyra’s 3Q23 Form 10-Q stated that reproxalap had shown broad-based and rapid-onset activity across multiple trials.

The same efficacy language appeared again in the March 7, 2024 Form 10-K, the February 28, 2025 Form 10-K, and the February 27, 2026 Form 10-K.

Then came March 17, 2026. Before the market opened, Aldeyra filed an 8-K disclosing receipt of the FDA’s 2026 Complete Response Letter, which stated that the NDA failed to demonstrate efficacy in adequate and well-controlled studies and that the totality of evidence did not support effectiveness. The market reaction was immediate: shares dropped $2.99 to $1.24, erasing 70.7% of value in a single session.

That is the corrective disclosure event at the heart of the loss causation narrative.

Investor Harm and Market Reaction

The alleged investor harm is direct and measurable. ALDX closed down approximately 70.7% on March 17, 2026, after the FDA disclosed concerns that the evidence package did not establish efficacy. For biotech investors, this kind of collapse is familiar: when a single-asset thesis fails, the repricing is brutal because the market is forced to revalue not just revenue timing, but platform legitimacy, capital runway assumptions, and dilution risk. The complaint ties these losses to the alleged inflation caused by repeated efficacy statements in SEC filings and invokes fraud-on-the-market reliance based on Nasdaq trading efficiency, analyst coverage, and broad public dissemination.

Litigation and Procedural Posture

The case is pending in the U.S. District Court for the District of Massachusetts on behalf of investors who purchased Aldeyra securities between November 3, 2023 and March 16, 2026. The complaint asserts claims under Section 10(b) of the Exchange Act and Rule 10b-5, as well as Section 20(a) control person liability against the individual defendants. Defendants include Aldeyra, CEO Todd Brady, finance chief Michael Alferi, and former interim CFO Bruce Greenberg.

The scienter theory is built on repeated executive signatures, the defendants’ senior roles and access to nonpublic company information, and the allegation that they knew or recklessly disregarded the inconsistency of the study outcomes

SEC Filings & Risk Factors

The SEC filing trail is the backbone of this ALDX securities class action.

The allegedly misleading statements appeared in:

• 3Q23 Form 10-Q
• FY23 Form 10-K
• FY24 Form 10-K
• FY25 Form 10-K

Across each filing, management repeated materially similar language about statistically significant, clinically relevant, and rapid-onset efficacy.

According to the complaint, the omitted adverse fact was not merely general biotech uncertainty, but that the clinical findings were inconsistent and any positive conclusions were unreliable and not meaningful. That distinction is important for investors evaluating biotech risk factors. General drug-development uncertainty is expected. Alleged inconsistency in the actual evidentiary record is something else entirely.

Conclusion: Implications for Investors

The Aldeyra lawsuit offers a familiar lesson in biotech securities litigation: repeated efficacy language in SEC filings can become the litigation record when regulators later reject the same evidence package.

For investors, the red flag is repetition without evolution. When identical efficacy language persists across multiple reporting cycles, investors may later question whether management’s public narrative kept pace with the underlying evidence.

This case also reinforces a broader sector lesson for development-stage biotech names: platform credibility is often overconcentrated in a single lead asset. When that asset breaks, the equity story breaks with it.

Now, investors are fighting back.

How to Join the Aldeyra Therapeutics (ALDX) Class Action

• Confirm you purchased ALDX securities between November 3, 2023 and March 16, 2026, inclusive
• Review eligibility details based on your transaction dates and losses
• Click here to check eligibility

Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.